Ignite Creation Date:
2024-10-26 @ 3:41 PM
Last Modification Date:
2024-10-26 @ 3:41 PM
Study NCT ID:
NCT06620692
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-23
Brief Title:
A Study to Investigate the Efficacy and Safety Profile of GM-XANTHO GM-XAN003 in Patients with Psoriasis
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Phase IIa Study to Investigate the Efficacy and Safety Profile of GM-XANTHO GM-XAN003 in Patients with Psoriasis
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is a Phase IIa clinical trial Around 65 subjects will be enrolled into this study to primarily assess the treatment efficacy of 5 GM-XANTHO in patients with psoriasis as well as the safety and tolerability of 5 GM-XANTHO Two third of the total subjects will be given the investigational product 5 GM-XANTHO and the other third will take placebo The treatment period will last for 28 consecutive days followed by a safety follow-up for 2 weeks During the study there will be 8 scheduled visits to the clinical center
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None